NASDAQ:BEAT - BioTelemetry Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$41.75 -0.70 (-1.65 %)
(As of 05/27/2018 03:44 AM ET)
Previous Close$41.75
Today's Range$41.40 - $43.10
52-Week Range$23.30 - $43.10
Volume366,112 shs
Average Volume350,023 shs
Market Capitalization$1.39 billion
P/E Ratio43.04
Dividend YieldN/A
Beta0.81

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry logoBioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Debt-to-Equity Ratio0.77
Current Ratio1.96
Quick Ratio1.83

Price-To-Earnings

Trailing P/E Ratio43.04
Forward P/E Ratio33.13
P/E Growth3.36

Sales & Book Value

Annual Sales$286.78 million
Price / Sales4.77
Cash Flow$1.84 per share
Price / Cash22.69
Book Value$7.82 per share
Price / Book5.34

Profitability

EPS (Most Recent Fiscal Year)$0.97
Net Income$-15,950,000.00
Net Margins-3.13%
Return on Equity16.63%
Return on Assets8.62%

Miscellaneous

Employees1,600
Outstanding Shares32,790,000

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) posted its quarterly earnings results on Wednesday, April, 25th. The medical research company reported $0.39 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.23 by $0.16. The medical research company had revenue of $94.50 million for the quarter, compared to analyst estimates of $91.55 million. BioTelemetry had a negative net margin of 3.13% and a positive return on equity of 16.63%. BioTelemetry's revenue for the quarter was up 69.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.16 earnings per share. View BioTelemetry's Earnings History.

What price target have analysts set for BEAT?

7 Wall Street analysts have issued 12-month target prices for BioTelemetry's stock. Their predictions range from $37.00 to $50.00. On average, they expect BioTelemetry's stock price to reach $44.00 in the next twelve months. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, Chief Exec. Officer, Pres and Director (Age 54)
  • Mrs. Heather C. Getz CPA, Chief Financial Officer and Exec. VP (Age 43)
  • Mr. Peter F. Ferola, Sr. VP of Corp. Devel., Gen. Counsel & Sec. (Age 49)
  • Mr. Fred Broadway III, Sr. VP of Sales and Marketing (Age 48)
  • Dr. Peter R. Kowey M.D., FACC, FACP, FACCP, FCP, Medical Director and Chairman of Medical Advisory Board

Has BioTelemetry been receiving favorable news coverage?

Media stories about BEAT stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioTelemetry earned a news sentiment score of 0.12 on Accern's scale. They also gave news headlines about the medical research company an impact score of 45.66 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.99%), Dimensional Fund Advisors LP (4.28%), Hood River Capital Management LLC (3.68%), Russell Investments Group Ltd. (2.44%), Allianz Asset Management GmbH (1.45%) and Allianz Asset Management GmbH (1.45%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which major investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Cannell Capital LLC, Mckinley Capital Management LLC Delaware, Cortina Asset Management LLC, Hodges Capital Management Inc., Thompson Siegel & Walmsley LLC, Millrace Asset Group Inc. and Allianz Asset Management GmbH. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz and Peter Ferola. View Insider Buying and Selling for BioTelemetry.

Which major investors are buying BioTelemetry stock?

BEAT stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Ancora Advisors LLC, Harvest Capital Strategies LLC, BlackRock Inc., Carillon Tower Advisers Inc., Natixis, Millennium Management LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $41.75.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.39 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioTelemetry (NASDAQ:BEAT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for BioTelemetry in the last 12 months. Their average twelve-month price target is $44.00, suggesting that the stock has a possible upside of 5.39%. The high price target for BEAT is $50.00 and the low price target for BEAT is $37.00. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.712.75
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.00$44.00$43.6667$43.50
Price Target Upside: 5.39% upside30.37% upside32.12% upside70.09% upside

BioTelemetry (NASDAQ:BEAT) Consensus Price Target History

Price Target History for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ:BEAT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2018BenchmarkReiterated RatingBuy ➝ Buy$44.00 ➝ $46.00HighView Rating Details
2/23/2018Dougherty & CoReiterated RatingBuy ➝ Buy$40.00 ➝ $41.00LowView Rating Details
10/26/2017Raymond JamesInitiated CoverageOutperform$37.00N/AView Rating Details
10/23/2017SunTrust BanksInitiated CoverageBuy$41.00N/AView Rating Details
9/15/2017Off Wall StreetInitiated CoverageSellMediumView Rating Details
8/10/2017SidotiReiterated RatingBuy$42.00 ➝ $49.00LowView Rating Details
7/14/2017Lake Street CapitalReiterated RatingBuy$35.00 ➝ $50.00HighView Rating Details
12/13/2016GabelliReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

BioTelemetry (NASDAQ:BEAT) Earnings History and Estimates Chart

Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ:BEAT) Earnings Estimates

2018 EPS Consensus Estimate: $1.09
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.22$0.24$0.23
Q2 20182$0.27$0.31$0.29
Q3 20181$0.28$0.28$0.28
Q4 20181$0.29$0.29$0.29
Q1 20191$0.30$0.30$0.30
Q2 20191$0.35$0.35$0.35
Q4 20191$0.40$0.40$0.40

BioTelemetry (NASDAQ BEAT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018Q1 2018$0.23$0.39$91.55 million$94.50 millionViewN/AView Earnings Details
2/22/2018Q4 2017$0.24$0.32$88.33 million$91.70 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.25$0.16$82.10 million$81.02 millionViewN/AView Earnings Details
8/8/2017Q2 2017$0.21$0.23$58.39 million$58.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.1430$0.16$55.11 million$55.88 millionViewListenView Earnings Details
2/22/2017Q4 2016$0.18$0.23$53.75 million$53.96 millionViewListenView Earnings Details
11/2/2016Q316$0.18$0.21$52.92 million$53.10 millionViewN/AView Earnings Details
8/2/2016Q2$0.17$0.20$50.27 million$52.68 millionViewListenView Earnings Details
4/26/2016Q1$0.10$0.20$46.54 million$48.60 millionViewListenView Earnings Details
2/17/2016Q415$0.11$0.15$45.89 million$46.70 millionViewListenView Earnings Details
11/9/2015Q3$0.11$0.13$46.05 million$43.49 millionViewN/AView Earnings Details
8/6/2015Q2$0.09$0.12$45.75 million$44.81 millionViewListenView Earnings Details
5/6/2015Q115$0.02$0.06$43.80 million$43.40 millionViewListenView Earnings Details
2/19/2015Q414$0.06$0.05$43.40 million$43.70 millionViewListenView Earnings Details
10/30/2014Q214$0.01$0.06$42.00 million$43.00 millionViewListenView Earnings Details
7/31/2014Q114$0.01$0.02$40.95 million$42.70 millionViewListenView Earnings Details
5/6/2014Q413($0.02)($0.04)$38.40 million$37.16 millionViewListenView Earnings Details
2/26/2014Q313($0.04)$0.05$32.26 million$33.10 millionViewListenView Earnings Details
11/5/2013($0.05)($0.12)$32.79 million$31.90 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.02$27.50 million$32.10 millionViewListenView Earnings Details
4/22/2013Q1 2013($0.03)$32.42 millionViewN/AView Earnings Details
2/13/2013Q4 2012($0.09)$26.80 million$30.00 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.08)$26.49 million$27.00 millionViewN/AView Earnings Details
8/8/2012($0.04)($0.01)ViewN/AView Earnings Details
5/8/2012($0.12)($0.10)ViewN/AView Earnings Details
2/22/2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2011($0.09)($0.21)ViewN/AView Earnings Details
8/8/2011($0.06)($0.05)ViewN/AView Earnings Details
5/3/2011($0.15)($0.02)ViewN/AView Earnings Details
2/17/2011($0.16)($0.13)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.05)($0.25)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.10)($0.09)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.18)($0.13)ViewN/AView Earnings Details
2/17/2010Q4 2009($0.12)($0.24)ViewN/AView Earnings Details
11/6/2009Q3 2009$0.03($0.11)ViewN/AView Earnings Details
8/5/2009Q2 2009$0.05$0.06ViewN/AView Earnings Details
4/30/2009Q1 2009$0.05$0.04ViewN/AView Earnings Details
2/17/2009Q4 2008$0.15$0.16ViewN/AView Earnings Details
10/30/2008Q3 2008$0.10$0.11ViewN/AView Earnings Details
7/22/2008Q2 2008$0.07$0.08ViewN/AView Earnings Details
4/29/2008Q1 2008$0.02ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioTelemetry (NASDAQ:BEAT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioTelemetry (NASDAQ BEAT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 92.25%
Insider Trading History for BioTelemetry (NASDAQ:BEAT)
Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ BEAT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018Peter FerolaSVPSell67,370$40.42$2,723,095.40View SEC Filing  
5/7/2018Daniel WisniewskiSVPSell40,000$41.09$1,643,600.00View SEC Filing  
5/2/2018Heather C GetzVPSell36,405$39.62$1,442,366.1080,561View SEC Filing  
4/26/2018Heather C GetzCFOSell65,570$38.03$2,493,627.1084,156View SEC Filing  
3/13/2018Fred BroadwayInsiderSell54,158$34.17$1,850,578.8664,880View SEC Filing  
5/15/2017Robert J. RubinDirectorSell15,000$28.14$422,100.00View SEC Filing  
3/20/2017Fred BroadwaySVPSell3,429$26.90$92,240.1025,420View SEC Filing  
2/27/2017George HrenkoSVPSell126,043$25.95$3,270,815.8523,172View SEC Filing  
2/21/2017Fred BroadwaySVPSell8,070$24.81$200,216.7028,849View SEC Filing  
9/19/2016George HrenkoSVPSell1,061$18.50$19,628.5037,568View SEC Filing  
9/13/2016Heather C GetzCFOSell5,866$18.23$106,937.1844,293View SEC Filing  
9/13/2016Joseph H CapperInsiderSell26,847$18.23$489,420.81189,838View SEC Filing  
9/13/2016Peter FerolaGeneral CounselSell4,352$18.23$79,336.9630,989View SEC Filing  
9/9/2016Fred BroadwaySVPSell3,146$17.84$56,124.6437,886View SEC Filing  
9/8/2016George HrenkoSVPSell3,491$18.06$63,047.4642,500View SEC Filing  
9/8/2016Heather C GetzCFOSell2,979$18.10$53,919.9050,159View SEC Filing  
9/8/2016Joseph H CapperInsiderSell13,632$18.10$246,739.20216,685View SEC Filing  
9/8/2016Peter FerolaGeneral CounselSell2,210$18.10$40,001.0028,847View SEC Filing  
9/7/2016Daniel WisniewskiSVPSell9,225$18.51$170,754.7538,672View SEC Filing  
9/7/2016Heather C GetzCFOSell18,945$18.52$350,861.4065,536View SEC Filing  
9/7/2016Joseph H CapperInsiderSell86,681$18.52$1,605,332.12287,045View SEC Filing  
9/7/2016Peter FerolaGeneral CounselSell14,053$18.52$260,261.5626,637View SEC Filing  
9/6/2016Fred BroadwaySVPSell4,662$18.28$85,221.3652,379View SEC Filing  
9/6/2016Heather C GetzCFOSell6,686$18.29$122,286.9465,536View SEC Filing  
9/6/2016Joseph H CapperCEOSell30,595$18.29$559,582.55287,045View SEC Filing  
9/6/2016Peter FerolaGeneral CounselSell4,960$18.29$90,718.4026,637View SEC Filing  
9/2/2016Fred BroadwaySVPSell4,466$18.75$83,737.5052,379View SEC Filing  
9/2/2016Heather C GetzCFOSell6,547$18.75$122,756.2565,536View SEC Filing  
9/2/2016Joseph H CapperCEOSell29,953$18.75$561,618.75287,045View SEC Filing  
9/2/2016Peter FerolaGeneral CounselSell4,856$18.75$91,050.0026,637View SEC Filing  
9/1/2016Fred BroadwaySVPSell7,525$19.25$144,856.2561,756View SEC Filing  
9/1/2016Heather C GetzCFOSell10,408$18.59$193,484.7278,721View SEC Filing  
9/1/2016Joseph H CapperInsiderSell47,622$18.59$885,292.98347,373View SEC Filing  
9/1/2016Peter FerolaGeneral CounselSell7,722$18.59$143,551.9835,177View SEC Filing  
8/30/2016Fred BroadwaySVPSell12,121$19.07$231,147.4771,719View SEC Filing  
8/30/2016Heather C GetzCFOSell17,482$19.07$333,381.7493,091View SEC Filing  
8/30/2016Joseph H CapperInsiderSell79,986$19.07$1,525,333.02413,117View SEC Filing  
8/30/2016Peter FerolaGeneral CounselSell12,970$19.07$247,337.9045,838View SEC Filing  
8/25/2016Fred BroadwaySVPSell5,877$19.16$112,603.3276,491View SEC Filing  
8/25/2016Heather C GetzCFOSell8,477$19.16$162,419.3299,973View SEC Filing  
8/25/2016Joseph H CapperInsiderSell38,785$19.16$743,120.60450,606View SEC Filing  
8/25/2016Peter FerolaGeneral CounselSell6,289$19.16$120,497.2450,944View SEC Filing  
8/24/2016George HrenkoSVPSell7,473$20.11$150,282.03103,888View SEC Filing  
8/24/2016Heather C GetzCFOSell8,778$20.11$176,525.58120,945View SEC Filing  
8/24/2016Joseph H CapperCEOSell40,160$20.11$807,617.60546,559View SEC Filing  
8/24/2016Peter FerolaGeneral CounselSell6,512$20.11$130,956.3266,503View SEC Filing  
8/23/2016George HrenkoSVPSell3,165$20.67$65,420.55103,888View SEC Filing  
8/23/2016Heather C GetzCFOSell3,717$20.67$76,830.39120,945View SEC Filing  
8/23/2016Joseph H CapperCEOSell17,008$20.67$351,555.36546,559View SEC Filing  
8/23/2016Peter FerolaGeneral CounselSell2,758$20.67$57,007.8666,503View SEC Filing  
8/22/2016George HrenkoSVPSell4,149$20.85$86,506.65103,888View SEC Filing  
8/22/2016Heather C GetzCFOSell4,874$20.85$101,622.90120,945View SEC Filing  
8/22/2016Joseph H CapperCEOSell22,298$20.85$464,913.30546,559View SEC Filing  
8/22/2016Peter FerolaGeneral CounselSell3,616$20.85$75,393.6066,503View SEC Filing  
8/19/2016Daniel WisniewskiSVPSell9,025$20.96$189,164.0068,501View SEC Filing  
8/19/2016Heather C GetzCFOSell9,026$20.96$189,184.96125,819View SEC Filing  
8/19/2016Joseph H CapperInsiderSell9,049$20.96$189,667.04568,857View SEC Filing  
8/19/2016Peter FerolaGeneral CounselSell9,035$20.96$189,373.6070,119View SEC Filing  
5/9/2014Ronald AhrensDirectorBuy6,000$7.37$44,220.00187,629View SEC Filing  
11/12/2013Ronald AhrensDirectorBuy5,000$11.73$58,650.00164,467View SEC Filing  
11/12/2012Ronald A AhrensDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/5/2012Joseph H CapperCEOBuy23,540$2.25$52,965.00View SEC Filing  
8/31/2012Joseph H CapperCEOBuy2,600$2.28$5,928.00View SEC Filing  
8/29/2012Joseph H CapperCEOBuy10,800$2.30$24,840.00View SEC Filing  
8/28/2012Joseph H CapperCEOBuy1,300$2.19$2,847.00View SEC Filing  
8/27/2012Joseph H CapperCEOBuy1,600$2.12$3,392.00View SEC Filing  
8/23/2012Joseph H CapperCEOBuy9,600$2.08$19,968.00View SEC Filing  
8/20/2012Joseph H CapperCEOBuy14,160$1.97$27,895.20View SEC Filing  
8/17/2012Joseph H CapperCEOBuy9,800$2.10$20,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioTelemetry (NASDAQ BEAT) News Headlines

Source:
DateHeadline
BioTelemetry Inc (BEAT) Expected to Post Quarterly Sales of $95.88 MillionBioTelemetry Inc (BEAT) Expected to Post Quarterly Sales of $95.88 Million
www.americanbankingnews.com - May 26 at 4:41 AM
Is Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) a Hot ETF Right Now?Is Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) a Hot ETF Right Now?
www.nasdaq.com - May 25 at 8:10 AM
BioTelemetry Inc (BEAT) Receives Consensus Recommendation of "Buy" from BrokeragesBioTelemetry Inc (BEAT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 24 at 1:52 PM
Dougherty & Co Brokers Boost Earnings Estimates for BioTelemetry Inc (BEAT)Dougherty & Co Brokers Boost Earnings Estimates for BioTelemetry Inc (BEAT)
www.americanbankingnews.com - May 24 at 9:39 AM
$0.31 Earnings Per Share Expected for BioTelemetry Inc (BEAT) This Quarter$0.31 Earnings Per Share Expected for BioTelemetry Inc (BEAT) This Quarter
www.americanbankingnews.com - May 24 at 3:12 AM
BioTelemetry Inc (BEAT) SVP Sells $2,723,095.40 in StockBioTelemetry Inc (BEAT) SVP Sells $2,723,095.40 in Stock
www.americanbankingnews.com - May 14 at 7:28 PM
Form 4 BIOTELEMETRY, INC. For: May 04 Filed by: RUBIN ROBERT J.Form 4 BIOTELEMETRY, INC. For: May 04 Filed by: RUBIN ROBERT J.
www.streetinsider.com - May 9 at 8:07 AM
Insider Selling: BioTelemetry Inc (BEAT) SVP Sells 40,000 Shares of StockInsider Selling: BioTelemetry Inc (BEAT) SVP Sells 40,000 Shares of Stock
www.americanbankingnews.com - May 8 at 7:39 PM
$95.88 Million in Sales Expected for BioTelemetry Inc (BEAT) This Quarter$95.88 Million in Sales Expected for BioTelemetry Inc (BEAT) This Quarter
www.americanbankingnews.com - May 8 at 2:29 AM
 Brokerages Expect BioTelemetry Inc (BEAT) to Post $0.31 Earnings Per Share Brokerages Expect BioTelemetry Inc (BEAT) to Post $0.31 Earnings Per Share
www.americanbankingnews.com - May 6 at 7:33 PM
BioTelemetry (BEAT) Raised to "Strong-Buy" at BidaskClubBioTelemetry (BEAT) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - May 5 at 12:31 AM
Heather C. Getz Sells 36,405 Shares of BioTelemetry Inc (BEAT) StockHeather C. Getz Sells 36,405 Shares of BioTelemetry Inc (BEAT) Stock
www.americanbankingnews.com - May 4 at 7:33 PM
BioTelemetry Inc (BEAT) Receives Average Recommendation of "Buy" from AnalystsBioTelemetry Inc (BEAT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 29 at 1:36 PM
Head-To-Head Survey: Acadia Healthcare (ACHC) & BioTelemetry (BEAT)Head-To-Head Survey: Acadia Healthcare (ACHC) & BioTelemetry (BEAT)
www.americanbankingnews.com - April 28 at 7:52 AM
Reviewing BioTelemetry (BEAT) & AAC (AAC)Reviewing BioTelemetry (BEAT) & AAC (AAC)
www.americanbankingnews.com - April 28 at 1:21 AM
Heather C. Getz Sells 65,570 Shares of BioTelemetry Inc (BEAT) StockHeather C. Getz Sells 65,570 Shares of BioTelemetry Inc (BEAT) Stock
www.americanbankingnews.com - April 27 at 7:10 PM
BioTelemetry (BEAT) Upgraded to "Buy" at ValuEngineBioTelemetry (BEAT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 27 at 1:36 PM
Consolidated Research: 2018 Summary Expectations for AdvanSix, Flagstar, CalAmp, Agree Realty, Cowen Group ...Consolidated Research: 2018 Summary Expectations for AdvanSix, Flagstar, CalAmp, Agree Realty, Cowen Group ...
globenewswire.com - April 27 at 8:13 AM
Consolidated Research: 2018 Summary Expectations for AdvanSix, Flagstar, CalAmp, Agree Realty, Cowen Group, and BioTelemetry — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for AdvanSix, Flagstar, CalAmp, Agree Realty, Cowen Group, and BioTelemetry — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - April 27 at 8:13 AM
BioTelemetry Inc to Post Q2 2018 Earnings of $0.31 Per Share, Dougherty & Co Forecasts (BEAT)BioTelemetry Inc to Post Q2 2018 Earnings of $0.31 Per Share, Dougherty & Co Forecasts (BEAT)
www.americanbankingnews.com - April 27 at 7:58 AM
BioTelemetry (BEAT) Posts  Earnings Results, Beats Estimates By $0.16 EPSBioTelemetry (BEAT) Posts Earnings Results, Beats Estimates By $0.16 EPS
www.americanbankingnews.com - April 26 at 6:50 PM
BioTelemetry Inc. (BEAT) Has Broken Out To A 7-Month High On Q1 ResultsBioTelemetry Inc. (BEAT) Has Broken Out To A 7-Month High On Q1 Results
www.nasdaq.com - April 26 at 5:24 PM
Edited Transcript of BEAT earnings conference call or presentation 25-Apr-18 9:00pm GMTEdited Transcript of BEAT earnings conference call or presentation 25-Apr-18 9:00pm GMT
finance.yahoo.com - April 26 at 5:24 PM
BioTelemetry (BEAT) Price Target Raised to $46.00 at BenchmarkBioTelemetry (BEAT) Price Target Raised to $46.00 at Benchmark
www.americanbankingnews.com - April 26 at 11:24 AM
BioTelemetrys (BEAT) CEO Joseph Capper on Q1 2018 Results - Earnings Call TranscriptBioTelemetry's (BEAT) CEO Joseph Capper on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 8:07 AM
BioTelemetry (BEAT) Lowered to "Sell" at Zacks Investment ResearchBioTelemetry (BEAT) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 5:42 PM
BioTelemetry, Inc. Reports First Quarter 2018 Financial ResultsBioTelemetry, Inc. Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 25 at 5:37 PM
BioTelemetry: 1Q Earnings SnapshotBioTelemetry: 1Q Earnings Snapshot
finance.yahoo.com - April 25 at 5:37 PM
BioTelemetry Inc (BEAT) to Post Q1 2018 Earnings of $0.24 Per Share, Dougherty & Co ForecastsBioTelemetry Inc (BEAT) to Post Q1 2018 Earnings of $0.24 Per Share, Dougherty & Co Forecasts
www.americanbankingnews.com - April 24 at 7:50 AM
BioTelemetry (BEAT) Scheduled to Post Earnings on TuesdayBioTelemetry (BEAT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 24 at 7:10 AM
Comparing Acadia Healthcare (ACHC) and BioTelemetry (BEAT)Comparing Acadia Healthcare (ACHC) and BioTelemetry (BEAT)
www.americanbankingnews.com - April 22 at 1:36 AM
Zacks: Brokerages Anticipate BioTelemetry Inc (BEAT) Will Announce Quarterly Sales of $91.63 MillionZacks: Brokerages Anticipate BioTelemetry Inc (BEAT) Will Announce Quarterly Sales of $91.63 Million
www.americanbankingnews.com - April 21 at 2:52 AM
Zacks: Analysts Expect BioTelemetry Inc (BEAT) Will Post Earnings of $0.27 Per ShareZacks: Analysts Expect BioTelemetry Inc (BEAT) Will Post Earnings of $0.27 Per Share
www.americanbankingnews.com - April 19 at 3:10 PM
BioTelemetry (BEAT) Upgraded by BidaskClub to "Buy"BioTelemetry (BEAT) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 17 at 10:29 AM
BioTelemetry (BEAT) Downgraded to Buy at BidaskClubBioTelemetry (BEAT) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 12:03 PM
BioTelemetry (BEAT) Now Covered by Analysts at Raymond James FinancialBioTelemetry (BEAT) Now Covered by Analysts at Raymond James Financial
www.americanbankingnews.com - April 4 at 7:30 PM
Head-To-Head Contrast: BioTelemetry (BEAT) and AAC (AAC)Head-To-Head Contrast: BioTelemetry (BEAT) and AAC (AAC)
www.americanbankingnews.com - April 4 at 3:21 PM
Head to Head Analysis: BioTelemetry (BEAT) vs. Hanger (HNGR)Head to Head Analysis: BioTelemetry (BEAT) vs. Hanger (HNGR)
www.americanbankingnews.com - April 4 at 3:21 PM
BioTelemetry, Inc. (BEAT) Receives Average Rating of "Hold" from AnalystsBioTelemetry, Inc. (BEAT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 1:47 PM
$91.55 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter$91.55 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter
www.americanbankingnews.com - April 4 at 2:32 AM
Contrasting Acadia Healthcare (ACHC) and BioTelemetry (BEAT)Contrasting Acadia Healthcare (ACHC) and BioTelemetry (BEAT)
www.americanbankingnews.com - April 3 at 11:52 PM
BioTelemetry, Inc. (BEAT) Expected to Post Earnings of $0.25 Per ShareBioTelemetry, Inc. (BEAT) Expected to Post Earnings of $0.25 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM
BioTelemetry (BEAT) Upgraded to "Buy" by BidaskClubBioTelemetry (BEAT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
Edited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMTEdited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMT
finance.yahoo.com - March 26 at 5:28 PM
Commit To Buy BioTelemetry At $24, Earn 10.2% Annualized Using Options - NasdaqCommit To Buy BioTelemetry At $24, Earn 10.2% Annualized Using Options - Nasdaq
www.nasdaq.com - March 24 at 8:41 AM
BioTelemetry (BEAT) Downgraded to Hold at BidaskClubBioTelemetry (BEAT) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 23 at 11:20 PM
WellCare Health Plans (WCG) vs. BioTelemetry (BEAT) Critical ComparisonWellCare Health Plans (WCG) vs. BioTelemetry (BEAT) Critical Comparison
www.americanbankingnews.com - March 23 at 8:52 AM
BioTelemetry (BEAT) Lowered to C at TheStreetBioTelemetry (BEAT) Lowered to C at TheStreet
www.americanbankingnews.com - March 22 at 8:28 AM
What Analysts Recommend for Amedisys and Peers in March 2018What Analysts Recommend for Amedisys and Peers in March 2018
finance.yahoo.com - March 19 at 8:10 AM
SunTrust Banks Comments on BioTelemetry, Inc.s Q1 2019 Earnings (BEAT)SunTrust Banks Comments on BioTelemetry, Inc.'s Q1 2019 Earnings (BEAT)
www.americanbankingnews.com - March 19 at 6:46 AM

SEC Filings

BioTelemetry (NASDAQ:BEAT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioTelemetry (NASDAQ:BEAT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioTelemetry (NASDAQ BEAT) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.